Business

Coronavirus | Cipla partners with Premier Medical Corporation to launch rapid antigen test kits in India


The company said it will commence supply of rapid point-of-care nasopharyngeal swab tests from this week.

Drug major Cipla on Wednesday announced its partnership with the Premier Medical Corporation Private Limited for commercialisation of the rapid antigen test kits for coronavirus (COVID-19) in India.

“In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Private Limited,” Cipla said in a regulatory filing.

The company said it will commence supply of rapid point-of-care nasopharyngeal swab tests from this week. The test will be marketed under the brand name ‘CIPtest.’ Shares of Cipla were trading 0.29% higher at ₹783.95 a piece on the BSE.

You have reached your limit for free articles this month.

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.

Personalised recommendations

A select list of articles that match your interests and tastes.

Faster pages

Move smoothly between articles as our pages load instantly.

Dashboard

A one-stop-shop for seeing the latest updates, and managing your preferences.

Briefing

We brief you on the latest and most important developments, three times a day.

Support Quality Journalism.

*Our Digital Subscription plans do not currently include the e-paper, crossword and print.



Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button